Skip to content
Clinical & Translational Register

What we are writing

Findings from the clinic and the laboratory.

† : (co-) First author, * : (co-) Corresponding author

Peer-reviewed output

8 papers · 4 years

expand_more Click a year to expand
2026
menu_book 2 papers trending_up 41 citations top paper
expand_more
  1. 18
    cites

    Phase I dose-escalation of larotrectinib plus selinexor in pediatric relapsed neuroblastoma: safety and preliminary activity

    Marcus Hollinger†, Aaron Lindqvist, Joseph Whittaker, Priya Vanderlin*

    Journal of Clinical Oncology · 2026 · 44(11):1284-1296

    linkDOI descriptionPubMed
  2. 41
    cites
    Top 2026

    Patient-derived organoids predict on-trial response to MEK-CDK4/6 combination therapy in pediatric atypical teratoid/rhabdoid tumors

    Sofia Reyes-Aguilar†, Kavya Anand, Priya Vanderlin*

    Cancer Cell · 2026 · 44(4):612-628.e7

    linkDOI descriptionPubMed
2025
menu_book 2 papers trending_up 33 citations top paper
expand_more
  1. 26
    cites

    A multi-omic decision-support framework for pediatric precision oncology: prospective validation across three centers

    David Chen†, Aaron Lindqvist, Sofia Reyes-Aguilar, Priya Vanderlin*

    JCO Precision Oncology · 2025 · 9:e2500218

    linkDOI descriptionPubMed
  2. 33
    cites
    Top 2025

    Circulating tumor DNA dynamics during Phase-I dose-finding in pediatric Ewing sarcoma: a correlative analysis

    Marcus Hollinger†, Hana Okafor, Priya Vanderlin*

    Clinical Cancer Research · 2025 · 31(18):3702-3714

    linkDOI descriptionPubMed
2024
menu_book 2 papers trending_up 62 citations top paper
expand_more
  1. 62
    cites
    Top 2024

    Lessons from a pediatric solid-tumor organoid biobank: derivation efficiency, fidelity, and limits as a predictive platform

    Sofia Reyes-Aguilar†, Kavya Anand, Joseph Whittaker, Priya Vanderlin*

    Blood Cancer Discovery · 2024 · 5(6):441-456

    linkDOI descriptionPubMed
  2. 14
    cites

    Continual reassessment method adapted for pediatric oncology Phase-I trials with rare-disease accrual constraints

    Aaron Lindqvist†, Priya Vanderlin*

    Pediatric Blood & Cancer · 2024 · 71(8):e31082

    linkDOI descriptionPubMed
2023
menu_book 2 papers trending_up 187 citations top paper
expand_more
  1. 187
    cites
    Top 2023

    Targeted therapy plus checkpoint inhibition in high-risk relapsed neuroblastoma: design rationale for a Phase-I/II combination trial

    Priya Vanderlin*

    Nature Medicine · 2023 · 29(11):2712-2719

    linkDOI descriptionPubMed
  2. 29
    cites

    Building a tissue-linked Phase-I infrastructure in a pediatric academic center: operational lessons from three years of accrual

    Hana Okafor†, Joseph Whittaker, Priya Vanderlin*

    Pediatric Blood & Cancer · 2023 · 70(4):e30188

    linkDOI descriptionPubMed